Is MRSH a Buy? What to Consider in 2026

Last updated July 2026

Short answer

The bull case for Marsh (MRSH) rests on Insurance brokerage scale and pricing cycle: Marsh is the largest insurance broker globally, and its commissions rise with commercial insurance premium rates. Revenue (TTM) is ~$27.5B. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: As an insurance broker, revenue is tied to the commercial insurance pricing cycle, and a prolonged soft market with falling premium rates would slow commission growth. Whether MRSH is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.

Marsh (ticker MRSH, formerly Marsh & McLennan Companies under MMC) is a global professional services firm built around two segments. Risk and Insurance Services houses Marsh, the world's largest insurance brokerage, and Guy Carpenter, a leading reinsurance broker. The Consulting segment houses Mercer, a large health, wealth, and career consultancy, and Oliver Wyman, a management consulting brand. Together these businesses employ roughly 90,000 people and generate the bulk of revenue from recurring commissions and advisory fees tied to commercial insurance placement, reinsurance, retirement, and workforce advisory work. The investment picture is that of a defensive, fee-driven compounder. Revenue is diversified across geographies and end markets, insurance broking benefits from multi-year commercial pricing cycles, and the consulting arm adds exposure to retirement, benefits, and strategy demand. The company has a long track record of mid-single-digit to high-single-digit organic growth, steady margin expansion, consistent buybacks, and decades of dividend increases. The trade-off is a premium valuation and sensitivity to the commercial insurance rate cycle, so the stock tends to behave like a quality holding rather than a rapid grower.

What's the case for buying MRSH?

1. Insurance brokerage scale and pricing cycle

Marsh is the largest insurance broker globally, and its commissions rise with commercial insurance premium rates. Multi-year firm pricing in property and specialty lines has supported organic growth, and the sheer scale of placements gives the firm data and negotiating leverage that smaller brokers lack.

2. Diversified consulting through Mercer and Oliver Wyman

The Consulting segment adds demand from retirement, health and benefits, and management strategy work. Mercer's recurring benefits and wealth advisory revenue and Oliver Wyman's project work diversify the company away from pure insurance broking and add higher-margin advisory streams.

3. Capital return and tuck-in acquisitions

The company has a long history of raising its dividend and repurchasing shares, with a recent roughly 10% quarterly dividend increase. It also compounds through frequent tuck-in acquisitions, notably via Marsh McLennan Agency in the US middle market, which adds fee revenue and geographic reach.

4. Recurring, fee-based revenue mix

A large share of revenue is recurring commissions and advisory fees rather than one-time sales, which gives the business relatively predictable cash flow across economic cycles and supports its defensive reputation among large-cap financial stocks.

What are the risks to MRSH?

As an insurance broker, revenue is tied to the commercial insurance pricing cycle, and a prolonged soft market with falling premium rates would slow commission growth. The consulting businesses are more cyclical and can weaken when corporate clients cut discretionary project and benefits spending. The stock trades at a premium valuation (a low-20s price to earnings multiple), so disappointing organic growth or margins could compress the multiple. Large acquisitions carry integration and goodwill risk, and the firm faces professional liability and regulatory exposure across many jurisdictions. Currency swings also affect reported results given the global footprint.

How is MRSH valued? (as of July 2026)

Price

$178.31

Market cap

$85.91B

P/E (TTM)

22.26

Forward P/E

15.79

Price / book

5.90

Beta

0.60

52-week range

$156.60 to $216.32

Snapshot for MRSH as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.

Revenue (TTM): ~$27.5B
Net income (TTM): ~$4.2B
Diluted EPS (TTM): ~$7.99
Market cap: ~$86B
P/E (TTM): ~22x
Dividend yield: ~2.1%

Marsh generated roughly $27 billion in trailing revenue with high-single-digit organic growth and expanding adjusted margins. It trades around a low-20s price to earnings multiple, a premium that reflects its recurring fee revenue and steady compounding rather than rapid growth. The next quarterly report is expected in late July 2026.

How do you decide if MRSH is a buy?

Rather than asking whether MRSH is a buy in the abstract, it tends to help to answer four questions:

Thesis: do you believe the case above, and is it still true today?
Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
Overlap: check whether you already hold MRSH indirectly through an index or sector ETF before adding more.

For the full picture, see the MRSH stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about MRSH against your real portfolio and see your actual exposure before deciding.

The bottom line on MRSH

The bottom line: Marsh's story right now is Insurance brokerage scale and pricing cycle, with revenue (ttm) at ~$27.5B. If you believe that narrative continues, the call is about sizing MRSH sensibly and checking overlap with what you own; if you doubt it (the risk: as an insurance broker, revenue is tied to the commercial insurance pricing cycle, and a prolonged soft market with falling premium rates would slow commission growth.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.

Build a basket around MRSH with Walnut

Use Marsh as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.

Create a free Walnut account

FAQ

Is MRSH a good stock to buy right now?

The case for Marsh right now is Insurance brokerage scale and pricing cycle, with revenue (ttm) at ~$27.5B. If you believe that thesis holds, MRSH is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is as an insurance broker, revenue is tied to the commercial insurance pricing cycle, and a prolonged soft market with falling premium rates would slow commission growth. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.

What does Marsh do?

Marsh (ticker MRSH, formerly Marsh & McLennan Companies under MMC) is a global professional services firm built around two segments.

What are the main risks of MRSH?

What company is ticker MRSH?

MRSH is Marsh, the NYSE ticker for the company formerly known as Marsh & McLennan Companies. The firm changed its ticker from MMC to MRSH on January 14, 2026, in connection with rebranding to Marsh.

Why did the ticker change from MMC to MRSH?

The change accompanied a corporate rebrand from Marsh McLennan to Marsh, effective January 2026. The legal entity and CUSIP were unchanged, and shareholders did not need to take any action; only the trading symbol changed.

What does Marsh actually do?

Marsh is a global professional services firm. Its Risk and Insurance Services segment includes Marsh (insurance broking) and Guy Carpenter (reinsurance), and its Consulting segment includes Mercer (health, wealth, and career) and Oliver Wyman (management consulting).

Does MRSH pay a dividend?

Yes. Marsh pays a quarterly dividend and recently raised it by about 10% to roughly 99 cents per share, giving a yield of about 2%. The company has a long record of consecutive annual dividend increases.

Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell MRSH; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.